Camel-IDS uses camel antibodies to fight cancer
After Ablynx, Argenx and Confo Therapeutics, Camel IDS is also working on a drug based on camel antibodies. The biotech company and VUB spin-off, develops a treatment that strikes cancer cells from inside the body. This therapy is more efficient than the classical radiation, which also damages healthy body cells.
You can read the full article in De Tijd.